Skin Cancer

On March 22, 2023, the FDA granted accelerated approval to retifanlimab-dlwr (Zynyz; Incyte Corporation), a programmed cell death 1–blocking antibody, for the treatment of adult patients with metastatic or recurrent locally advanced Merkel-cell carcinoma.
Read Article

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: